Cargando…

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?

Detalles Bibliográficos
Autor principal:	Lee, Je-Jung
Formato:	Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2010
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2983034/ https://www.ncbi.nlm.nih.gov/pubmed/21120197 http://dx.doi.org/10.5045/kjh.2010.45.3.143

Ejemplares similares

Syndecan-1 (CD138), Carcinomas and EMT
por: Couchman, John R.
Publicado: (2021)

The Intensity and Pattern of Syndecan-1 (CD138) Expression in Normal and Diseased Livers
por: Atique, Muhammad, et al.
Publicado: (2023)

Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study
por: Kim, Ji Myung, et al.
Publicado: (2010)

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins
por: Jung, O, et al.
Publicado: (2016)

Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations
por: Sharma, Monica, et al.
Publicado: (2018)

Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues
por: Kind, Simon, et al.
Publicado: (2019)

Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus
por: Liu, Lunhua, et al.
Publicado: (2020)

Utility of CD138/syndecan-1 immunohistochemistry for localization of plasmacytes is tissue-dependent in B6 mice
por: Meyerholz, David K., et al.
Publicado: (2022)

Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
por: Mundt, Filip, et al.
Publicado: (2014)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies
por: Cigliana, Giovanni, et al.
Publicado: (2015)

Prognostic Value of Hepatocyte Growth Factor, Syndecan-1, and Osteopontin in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
por: Minarik, Jiri, et al.
Publicado: (2012)

Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma()
por: Krishnan, Sabna Rajeev, et al.
Publicado: (2016)

Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma
por: Łacina, Piotr, et al.
Publicado: (2022)

High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma
por: Ibata, Soushi, et al.
Publicado: (2018)

Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells
por: Lamorte, S, et al.
Publicado: (2012)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
por: Omstead, David T., et al.
Publicado: (2020)

An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ
por: Götte, Martin, et al.
Publicado: (2007)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
por: Soloveva, Maiia, et al.
Publicado: (2023)

Low Soluble Syndecan-1 Precedes Preeclampsia
por: Gandley, Robin E., et al.
Publicado: (2016)

Syndecan-1 (CD138) deficiency increases Staphylococcus aureus infection but has no effect on pathology in a mouse model of peritoneal dialysis
por: Kowalewska, Paulina M., et al.
Publicado: (2016)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells
por: Kishimoto, Renata Kiyomi, et al.
Publicado: (2016)

Raised Serum Levels of Syndecan-1 (CD138), in a Case of Acute Idiopathic Systemic Capillary Leak Syndrome (SCLS) (Clarkson’s Disease)
por: Bøe, Ole Wilhelm, et al.
Publicado: (2018)

Soluble syndecan-1 and glycosaminoglycans in preeclamptic and normotensive pregnancies
por: Hassani Lahsinoui, H., et al.
Publicado: (2021)

The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4(+) T cell polarization in inflammatory and non-inflammatory breast cancer patients
por: Saleh, Moshira Ezzat, et al.
Publicado: (2019)

Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout
por: Jacak, Jaroslaw, et al.
Publicado: (2013)

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
por: KAWANO, YAWARA, et al.
Publicado: (2012)

Comment on: “Validation of interphase fluorescence in situ hybridization (iFISH) of CD138 positive cells in multiple myeloma”()
por: Zalcberg Renault, Ilana
Publicado: (2016)

CD138(-) multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient
por: Wu, Dong, et al.
Publicado: (2020)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
por: Qasaimeh, Mohammad A., et al.
Publicado: (2017)

A Comparison of Ki67, Syndecan-1 (CD138), and Molecular RANK, RANKL, and OPG Triad Expression in Odontogenic Keratocyts, Unicystic Ameloblastoma, and Dentigerous Cysts
por: Brito-Mendoza, Luisana, et al.
Publicado: (2018)

Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma
por: Choudhuri, Jui, et al.
Publicado: (2023)

Prognostic significance of syndecan-1 expression in cervical cancers
por: Kim, Yu Im, et al.
Publicado: (2011)

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
por: Bae, Jooeun, et al.
Publicado: (2014)

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma
por: Papadimitriou, Maria-Alexandra, et al.
Publicado: (2023)

Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
por: Cengiz, Arzu, et al.
Publicado: (2018)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i13ghqjgv4oa6n7rbq58nlloc9